These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 19519964

  • 1. The effect of bosentan in patients with a failing Fontan circulation.
    Ovaert C, Thijs D, Dewolf D, Ottenkamp J, Dessy H, Moons P, Gewillig M, Mertens L.
    Cardiol Young; 2009 Aug; 19(4):331-9. PubMed ID: 19519964
    [Abstract] [Full Text] [Related]

  • 2. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial.
    Schuuring MJ, Vis JC, van Dijk AP, van Melle JP, Vliegen HW, Pieper PG, Sieswerda GT, de Bruin-Bon RH, Mulder BJ, Bouma BJ.
    Eur J Heart Fail; 2013 Jun; 15(6):690-8. PubMed ID: 23361871
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP, Dimopoulos K, Kaya MG, Harries C, Uebing A, Li W, Koltsida E, Gibbs JS, Gatzoulis MA.
    Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
    [Abstract] [Full Text] [Related]

  • 4. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.
    Hirono K, Yoshimura N, Taguchi M, Watanabe K, Nakamura T, Ichida F, Miyawaki T.
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):346-51. PubMed ID: 20434177
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G.
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
    Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S.
    Heart; 2007 Mar; 93(3):350-4. PubMed ID: 16980516
    [Abstract] [Full Text] [Related]

  • 9. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study.
    Hebert A, Mikkelsen UR, Thilen U, Idorn L, Jensen AS, Nagy E, Hanseus K, Sørensen KE, Søndergaard L.
    Circulation; 2014 Dec 02; 130(23):2021-30. PubMed ID: 25446057
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of endothelin blockade in adults with Fontan physiology.
    Derk G, Houser L, Miner P, Williams R, Moriarty J, Finn P, Alejos J, Aboulhosn J.
    Congenit Heart Dis; 2015 Dec 02; 10(1):E11-6. PubMed ID: 24890846
    [Abstract] [Full Text] [Related]

  • 11. Hemodynamic impact of pulmonary vasodilators on single ventricle physiology.
    Castaldi B, Bordin G, Padalino M, Cuppini E, Vida V, Milanesi O.
    Cardiovasc Ther; 2018 Feb 02; 36(1):. PubMed ID: 29193758
    [Abstract] [Full Text] [Related]

  • 12. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
    Duffels MG, Vis JC, van Loon RL, Nieuwkerk PT, van Dijk AP, Hoendermis ES, de Bruin-Bon RH, Bouma BJ, Bresser P, Berger RM, Mulder BJ.
    Am J Cardiol; 2009 May 01; 103(9):1309-15. PubMed ID: 19406277
    [Abstract] [Full Text] [Related]

  • 13. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S.
    Heart; 2005 Nov 01; 91(11):1447-52. PubMed ID: 15761050
    [Abstract] [Full Text] [Related]

  • 14. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K, Jakrapanichakul D, Sompradikul S.
    J Med Assoc Thai; 2008 Feb 01; 91(2):196-202. PubMed ID: 18389984
    [Abstract] [Full Text] [Related]

  • 15. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP, Humbert M, Rubin L, Black CM.
    Ann Rheum Dis; 2006 Oct 01; 65(10):1336-40. PubMed ID: 16793845
    [Abstract] [Full Text] [Related]

  • 16. Safety and tolerability of bosentan in adults with Eisenmenger physiology.
    Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, Mikhail GW, Gibbs JS.
    Int J Cardiol; 2005 Jan 01; 98(1):147-51. PubMed ID: 15676179
    [Abstract] [Full Text] [Related]

  • 17. Rationale and design of a trial on the role of bosentan in Fontan patients: improvement of exercise capacity?
    Schuuring MJ, Vis JC, Bouma BJ, van Dijk AP, van Melle JP, Pieper PG, Vliegen HW, Sieswerda GT, Mulder BJ.
    Contemp Clin Trials; 2011 Jul 01; 32(4):586-91. PubMed ID: 21527360
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation.
    Agnoletti G, Gala S, Ferroni F, Bordese R, Appendini L, Pace Napoleone C, Bergamasco L.
    J Thorac Cardiovasc Surg; 2017 Jun 01; 153(6):1468-1475. PubMed ID: 28283234
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
    Monfredi O, Griffiths L, Clarke B, Mahadevan VS.
    Am J Cardiol; 2011 Nov 15; 108(10):1483-8. PubMed ID: 21943933
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.